Scientists have developed a new chimeric antibody that suppresses malignant cancers in dogs, showing promise for safe and effective treatment of intractable cancers.
Similar to our aging society, dogs live longer than before and an increasing number of them die from cancer nowadays. As seen in humans, dogs have malignant cancers that cannot be treated by existing therapies such as surgery, radiotherapy and chemotherapy. Oral malignant melanoma (OMM), a highly invasive cancer in dogs, is one such example.
In humans, some malignant cancer cells express PD-L1 proteins that bind to their receptor PD-1 on T cells, resulting in the suppression of the T cell’s immune function. Thus, PD-L1/PD-1 interaction is considered an “immune escape mechanism” that cancer cells have. Antibodies that block PD-1/PD-L1 binding have proven effective in inducing anti-tumor immune responses and have been widely used in immunotherapy in the last five years. However, in dogs, no such clinical studies have been reported so far.
Professor Satoru Konnai of Hokkaido University and his collaborators in Japan have developed a chimeric anti-PD-L1 antibody that induces immune responses and therefore tumor regression in dogs with malignant cancers.
The team first revealed that PD-L1 is expressed in the cells of OMM and another type of cancer called undifferentiated sarcoma, confirming that those two cancers are likely targeted by the immunotherapy. They then utilized a rat anti-PD-L1 antibody to develop a rat-dog chimeric antibody which should help avoid rejection by the immune system and allergic reactions when administered to dogs.
In their pilot clinical study, seven dogs with OMM and two dogs with undifferentiated sarcoma were treated with the chimeric antibody every two weeks. One of the OMM dogs showed obvious tumor regression after ten weeks of administration while one dog with undifferentiated sarcoma showed a significant decrease in tumor burden after three weeks. None of them showed adverse effects such as an allergic reaction. Moreover, their data suggested the treatment may have prolonged survival in dogs with OMM after pulmonary metastasis.
“Chimerization of the antibody is now proven as a simple and effective strategy to develop therapeutic antibodies in veterinary medicine. Although further clinical studies are needed, other PD-L1-positive cancers could be targeted by the antibody we have developed,” says Satoru Konnai. “Given the similarity between humans and dogs in cancer biology, our study should provide a beneficial model for human preclinical studies.”
Learn more: New therapeutic antibody for dog cancers
The Latest on: Chimeric antibody
- Dr. Madduri on Treatment After CAR T Cells in Myeloma on December 10, 2018 at 2:23 pm
Most CAR T cell products are BCMA-directed, and BCMA antibody drug conjugates and other targeted therapies ... Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after c... […]
- Monoclonal Antibody Therapy Market Demand, Competition, Trends, Industry Analysis by Players and Global Forecasts to 2022 on December 4, 2018 at 4:27 pm
Segments for Global Monoclonal Antibody Therapy Market Monoclonal antibody therapy market has been segmented on the basis of source which comprises of recombinant, chimeric, humanized, human, and othe... […]
- AbCellera Collaborates with Autolus on Antibody Discovery Project on November 29, 2018 at 2:08 am
Under the partnership, AbCellera is applying its microfluidic single-cell screening platform to find novel antibodies which can be used for the development of new Chimeric Antigen Receptor (CAR ... […]
- Introduction to Three Generations of Antibody Development on November 5, 2018 at 11:30 pm
1. Humanization of mouse mAb Chimeric antibodies: The earliest method was to splice the mAb V region of mice with the human antibody C region to form “human-mouse chimeric antibodies”. The affinity an... […]
- The Evolution of Antibody Patents on October 8, 2018 at 4:30 am
Centocor had used a mouse model to develop its antibody and then combined that mouse antibody with human elements to make a chimeric antibody. However, in its patent, while it disclosed and characteri... […]
- Transfectomas provide novel chimeric antibodies on October 4, 2018 at 2:44 am
Methods have been developed to transfect immunoglobulin genes into lymphoid cells. The transfected genes are faithfully expressed, and assembly can occur both between the transfected and endogenous ch... […]
- Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection on August 8, 2018 at 11:28 am
1 Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands. 2 Department of Molecular and Cell Biology, National Center for Biotechnology–Spanish National Research Council (CNB-CSIC), ... […]
- Monoclonal Antibodies Market 2018 - Leading Products in the Chimeric, Humanized, and Human Market on April 12, 2018 at 10:41 am
The " What's Trending in Monoclonal Antibodies (Market by Structure [Chimeric, Humanized], by Target [EGFR, TNF, HER2, CD20,PD-1, Other] and by Disease [Autoimmune, Oncology, Neurological, Other])" re... […]
- Global Chimeric Antibody Industry Sales, Revenue, Gross Margin, Market Share by Top Companies on January 5, 2018 at 4:00 pm
Global Chimeric Antibody Industry 2017 Market Research Report provides the details about Industry Overview, Manufacturing Cost Structure, Capacity, Growth Rate, Gross Margin, Major Manufacturers, Deve... […]
via Google News and Bing News